Press release
Alzheimer’s Therapeutics Market Is Anticipated To Witness Lucrative Growth, Owing To The Increasing Prevalence And Incidence Rates Of This Disease And Growing Geriatric Population Base Till 2024
Growing knowledge about the Alzheimer’s disease (AD) and its high prevalence and incidence in developing economies are few of the major drivers supporting the market growth. Several governments, nonprofit, and private organizations worldwide are actively engaged in increasing people’s awareness regarding progressive AD, such as Alzheimer’s Association, the Alzheimer’s Society of Canada, Alzheimer’s Europe organization, and various other small organizations.
Furthermore, the increased government funding for providing better care and support to the people with partial dementia is another important factor anticipated to enlarge market growth. For instance, organizations like Florida Department of Health, the National Institute of Health, and Alzheimer’s Association in partnership with other private and government organizations provide funds to the research centers.
The presence of various pipeline drugs is anticipated to provide the market with potential growth opportunities. For instance, LMTX by TauRx Pharmaceutical Ltd.; idalopirdine (Lu AE58054) by Lundbeck; crenezumab by AC Immune SA; and BAN2401 by Eisai
Moreover, novel therapeutics with minimal dosage requirement has been introduced resulting in cost-effective alternatives, which is further expected to boost the market growth. For instance, Namzaric by Actavis was developed in two forms: 10 mg and 28 mg. 10 mg requires to be administered twice a day, while 28 mg requires to be administered once in a day.
Browse full research report on Global Alzheimer’s Therapeutics Market: http://www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market
Further Key Findings from the Study Suggest:
• The cholinesterase inhibitors segment was dominant in 2013 but lost hold on the market till 2015. Patent expiry of key drugs such as Aricept, Exelon, and Razadyne was the major factor for decline in market share.
• Exelon transdermal patch is estimated to lose exclusivity in 2019. It is a highly prescribed drug for the treatment of mild to moderate AD, which contributed toward its revenue generation in 2015.
• N-methyl-D-aspartate receptor antagonist, on the other hand, is expected to witness a significant growth of around 16.0% over the forecast period owing to introduction of extended relase formulation of Namenda.
• Other drug therapies such as monocloclonal antibodies and drugs targeting Tau proteins are in being studied in latter phases of the clinical trials. Presence of a strong of pipeline drugs for target disease are attributing toward fastest growth of these drugs
• North America dominated the overall market in terms of revenue with share of over 33.0% in 2015, which is majorly facilitated by the availability of sophisticated healthcare facilities and infrastructure.
• Some key players operating in this industry are Pfizer, Inc.; Merck & Co. Inc.; Novartis AG; Eisai Co. Ltd., H. Lundbeck A/S, AC Immune; TauRx Pharmaceuticals Ltd.; Actavis plc.; Forest Laboratories; and Teva Pharmaceuticals Industries Ltd.
• Market players are expanding their product portfolio by developing and launching generic versions of drugs to sustain its market position. For instance, in 2015, Dr. Reddy’s Laboratories Ltd. and Mylan launched the generic version of Namenda (Forest laboratories – Actavis).
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the Alzheimer’s therapeutics market on the basis of drug class and region:
Alzheimer’s Therapeutics Market Drug Outlook (Market Revenue in USD Million, 2013 - 2024)
• Cholinesterase Inhibitors
• N-methyl-D-aspartate (NMDA) receptor antagonist
Alzheimer’s Therapeutics Market Regional Outlook, (Market Revenue in USD Million, 2013 - 2024)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
• Asia Pacific
o China
o Japan
• Latin America
o Brazil
o Mexico
• MEA
o South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Press Contact
Sherry James - Corporate Relations Specialist
28 2nd Street, Suite 3036
San Francisco, CA 94105
United States
Phone: 1-415-349-0058
Email: sales@grandviewresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer’s Therapeutics Market Is Anticipated To Witness Lucrative Growth, Owing To The Increasing Prevalence And Incidence Rates Of This Disease And Growing Geriatric Population Base Till 2024 here
News-ID: 359243 • Views: …
More Releases from Grand View Research, Inc.
Generative AI Market Size, Share, And Industry Outlook Report, 2030
Generative AI Market Growth & Trends
The global generative AI market size is anticipated to reach USD 109.37 billion by 2030, according to a new report by Grand View Research, Inc., registering a CAGR of 37.6% from 2025 to 2030. Growing demand to modernize workflow across industries is expected to drive the demand for generative AI applications among industries. Other factors that propel the market growth include the evolution of AI…
Maternal Mental Health Market To Reach $45.72 Billion By 2030 | Therapy Mama, Ca …
The global maternal mental health market size is expected to reach USD 45.72 billion by 2030, growing at a CAGR of 28.43%, according to a new report by Grand View Research, Inc. Maternal mental health issues are a global concern that affects women of various countries and cultures. It refers to the emotional well-being of women during the pregnancy and postpartum period. The market is driven by the increasing incidence…
Downstream Processing Market Size, Share & Trends Analysis Report, 2030
The global downstream processing market size is expected to reach USD 94.79 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.84% from 2023 to 2030. The capacity requirements during the development of biologic drugs have changed over the past few years, wherein the demand for manufacturing high-volume products has shifted to developing small-volume, high-potency…
Electric Mobility Industry: E- Light Commercial Vehicle Thereby Contributing To …
The global electric mobility industry size stood at USD 101.67 billion in 2022 and will exhibit a CAGR of 19.9% from 2023 to 2030, according to the "Electric Mobility Industry Data Book, 2023 - 2030," published by Grand View Research. The growth comes on the back of an exponential rise in smart cities and a gradual uptick in charging infrastructure. Further, the strong outlook of electric mobility will rely on the launch…
More Releases for Alzheimer’s
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure…
Media Advisory: Alzheimer’s Disease Resource Center, Inc. Presents 10th Annual …
Who: Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Disease Resource Center, Inc. (ADRC)
Participating Walk for Alzheimer’s teams and individuals
Mickey B, Radio Personality, WGBB Radio and Master of Ceremonies
Ronald McDonald
The Liberty Bells, USO troupe
What: Alzheimer’s Disease Resource Center, Inc. (ADRC) is presenting its 10th Annual Old Bethpage Walk for Alzheimer’s & Mexican Fiesta. There will be an opening ceremony with Mickey B, Radio Personality, WGBB Radio, as the Master of…
Home Care Assistance Partners with the Alzheimer’s Association to Promote Earl …
(Palo Alto, CA – November 29, 2011) Home Care Assistance, North America’s leading provider of in-home care for seniors, announced today that, along with companies including Genworth, Starbucks, Intel and Pfizer, they are now a Champion Partner of the Alzheimer’s Early Detection Alliance (AEDA). The AEDA is a program renowned for raising Alzheimer’s awareness and promoting early detection of the disease. As a member of this important alliance, Home…
Alzheimer’s Association Long Island Announces Release of Latest Report on Alzh …
Alzheimer’s Association Long Island announced the release of the most recent report about Alzheimer’s disease. “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” provides a look into the unrelenting challenges brought on by this disease by offering insights and perspectives from individuals across the country who participated in the Alzheimer’s Association’s public input process. The Association and over 70 of its chapters hosted 132 input sessions throughout…
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to…
Alzheimer’s Association Long Island Presents Public Input Session for National …
On August 24, Alzheimer’s Association Long Island will hold a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials from the U.S. Department of Health and Human Services,…
